A Phase 1 interventional study of AGN-199201 Formulation A and AGN-199201 Formulation B in Rosacea and Erythema, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.
Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.
Among the 145 studies in Rosacea with a site in United States, this one is the 73rd largest by enrollment of the 137 interventional ones that give a count, is one of 11 that started in 2012, is one of 18 in phase 1, and was the 42nd registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Narrows Institute for Biomedical Research · Sites in United States
Ages 18+ · Healthy volunteers
University of Miami · Sites in United States
Ages 18+
Wright State University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 34 · Phase 4 20
First in 2002; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 78 across the 137 interventional studies, 236 across the 8 observational. Of the 127 that completed or were terminated, 76 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 145 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Rosacea — fewer than ten, so there is no comparison to draw.
3 of the studies in Rosacea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07443202Tarsus Pharmaceuticals, Inc.Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | 2026-12-31 |
| NCT06801717University of MiamiRosacea Radiofrequency Microneedling | 2027-07-01 |
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 145 studies in Rosacea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
Drug: AGN-199201 Formulation A · Drug: AGN-199201 Formulation B
AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
Drug: AGN-199201 Formulation B · Drug: AGN-199201 Formulation C
AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
Drug: AGN-199201 Formulation A · Drug: AGN-199201 Formulation C
AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
Drug: AGN-199201 Formulation A · Drug: AGN-199201 Vehicle
AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
Drug: AGN-199201 Formulation B · Drug: AGN-199201 Vehicle
AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
Drug: AGN-199201 Formulation C · Drug: AGN-199201 Vehicle
AGN-199201 Formulation A applied to both sides of the face twice daily.
Drug: AGN-199201 Formulation A
AGN-199201 Formulation B applied to both sides of the face twice daily.
Drug: AGN-199201 Formulation B
AGN-199201 Formulation C applied to both sides of the face twice daily.
Drug: AGN-199201 Formulation C
AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
Drug: AGN-199201 Vehicle
AGN-199201 Formulation A applied to the face as per protocol twice daily.
AGN-199201 Formulation B applied to the face as per protocol twice daily.
AGN-199201 Formulation C applied to the face as per protocol twice daily.
AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
Time frame: Baseline, Day 1-hour 6
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 5
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
Time frame: Baseline, Day 5-hour 6
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on CEA
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score at Day 1 and Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness.
Time frame: Baseline, Day 1-hour 6, Day 5-hour 6
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on SSA
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1 and Day 5. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
Time frame: Baseline, Day1-hour 6, Day 5-hour 6
| Milestone | AGN-199201 Formulation A and B | AGN-199201 Formulation B and C | AGN-199201 Formulation C and A | AGN-199201 Formulation A and Vehicle | AGN-199201 Formulation B and Vehicle | AGN-199201 Formulation C and Vehicle | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 4 |
| Completed | 8 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
| Percentage of responders | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle |
|---|---|---|---|---|
| Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1 | 15.6 | 21.9 | 28.1 | 0.0 |
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score at Day 1 and Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness.
| Percentage of responders | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle |
|---|---|---|---|---|
| Day 1-hour 6 | 34.4 | 34.4 | 40.6 | 0.0 |
| Day 5-hour 6 (Facial Sides n=32,31,31,32) | 15.6 | 6.5 | 6.5 | 6.3 |
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1 and Day 5. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
| Percentage of responders | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle |
|---|---|---|---|---|
| Day1-hour 6 | 31.3 | 46.9 | 56.3 | 3.1 |
| Day 5-hour 6 (Facial Sides n=32,31,31,32) | 34.4 | 41.9 | 58.1 | 28.1 |
The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
| Percentage of responders | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle |
|---|---|---|---|---|
| Percentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 5 | 6.3 | 6.5 | 6.5 | 3.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AGN-199201 Formulation A and B | — | 0/8 (0%) | 3/8 (37.5%) |
| AGN-199201 Formulation B and C | — | 0/8 (0%) | 5/8 (62.5%) |
| AGN-199201 Formulation C and A | — | 0/8 (0%) | 3/8 (37.5%) |
| AGN-199201 Formulation A and Vehicle | — | 0/8 (0%) | 6/8 (75%) |
| AGN-199201 Formulation B and Vehicle | — | 0/8 (0%) | 6/8 (75%) |
| AGN-199201 Formulation C and Vehicle | — | 0/8 (0%) | 4/8 (50%) |
| AGN-199201 Formulation A | — | 0/4 (0%) | 3/4 (75%) |
| AGN-199201 Formulation B | — | 0/4 (0%) | 3/4 (75%) |
| AGN-199201 Formulation C | — | 0/4 (0%) | 3/4 (75%) |
| AGN-199201 Vehicle | — | 0/4 (0%) | 2/4 (50%) |
| Event | AGN-199201 Formulation A and B | AGN-199201 Formulation B and C | AGN-199201 Formulation C and A | AGN-199201 Formulation A and Vehicle | AGN-199201 Formulation B and Vehicle | AGN-199201 Formulation C and Vehicle | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle |
|---|---|---|---|---|---|---|---|---|---|---|
| Application site painGeneral disorders | 1/8 | 1/8 | 0/8 | 1/8 | 0/8 | 2/8 | 0/4 | 0/4 | 2/4 | 0/4 |
| Application site papulesGeneral disorders | 1/8 | 3/8 | 0/8 | 2/8 | 2/8 | 0/8 | 2/4 | 1/4 | 2/4 | 0/4 |
| Application site paraesthesiaGeneral disorders | 1/8 | 2/8 | 2/8 | 2/8 | 0/8 | 1/8 | 0/4 | 2/4 | 0/4 | 0/4 |
| Application site pustulesInfections and infestations | 0/8 | 0/8 | 0/8 | 1/8 | 1/8 | 0/8 | 1/4 | 1/4 | 2/4 | 0/4 |
| HeadacheNervous system disorders | 0/8 | 2/8 | 0/8 | 1/8 | 3/8 | 3/8 | 1/4 | 0/4 | 0/4 | 0/4 |
| NauseaGastrointestinal disorders | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/4 | 1/4 | 0/4 | 0/4 |
| Application site erythemaGeneral disorders | 0/8 | 1/8 | 0/8 | 0/8 | 1/8 | 1/8 | 0/4 | 1/4 | 0/4 | 0/4 |
| Application site noduleGeneral disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/4 | 0/4 | 0/4 | 1/4 |
| Application site pruritusGeneral disorders | 1/8 | 1/8 | 0/8 | 0/8 | 1/8 | 1/8 | 0/4 | 0/4 | 1/4 | 0/4 |
| Application site rashGeneral disorders | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/4 | 1/4 | 0/4 | 0/4 |
| Age, Customized(Participants) | AGN-199201 Formulation A and B | AGN-199201 Formulation B and C | AGN-199201 Formulation C and A | AGN-199201 Formulation A and Vehicle | AGN-199201 Formulation B and Vehicle | AGN-199201 Formulation C and Vehicle | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 45 years | 1 | 1 | 1 | 4 | 0 | 1 | 0 | 1 | 1 | 0 | 10 |
| 45 to 65 years | 7 | 6 | 6 | 4 | 8 | 7 | 3 | 3 | 2 | 4 | 50 |
| > 65 years | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 |
| Sex: Female, Male(Participants) | AGN-199201 Formulation A and B | AGN-199201 Formulation B and C | AGN-199201 Formulation C and A | AGN-199201 Formulation A and Vehicle | AGN-199201 Formulation B and Vehicle | AGN-199201 Formulation C and Vehicle | AGN-199201 Formulation A | AGN-199201 Formulation B | AGN-199201 Formulation C | AGN-199201 Vehicle | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 8 | 6 | 7 | 5 | 7 | 2 | 4 | 2 | 3 | 49 |
| Male | 3 | 0 | 2 | 1 | 3 | 1 | 2 | 0 | 2 | 1 | 15 |
The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxymetazoline